MedPath

Papaverine Hydrochloride

PAPAVERINE HYDROCHLORIDE INJECTION, USP

Approved
Approval ID

5ba6e650-a5b5-4381-a62a-b7a6df73e8e6

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 9, 2023

Manufacturers
FDA

Oryza Pharmaceuticals Inc.

DUNS: 080337493

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Papaverine Hydrochloride

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code72516-024
Product Classification
G
Generic Name
Papaverine Hydrochloride
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateJanuary 26, 2021
FDA Product Classification

INGREDIENTS (5)

PAPAVERINE HYDROCHLORIDEActive
Quantity: 30 mg in 1 mL
Code: 23473EC6BQ
Classification: ACTIB
SODIUM CITRATEInactive
Code: 1Q73Q2JULR
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
EDETATE DISODIUMInactive
Code: 7FLD91C86K
Classification: IACT
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QP
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.